That approval status is a hard regulatory fact, and it is the single biggest reason a CagriSema-versus-tirzepatide comparison is not a comparison of equals: one product has cleared a full regulatory efficacy-and-safety review, and the other has not yet
Because the vitamin deposits into muscle rather than entering the vasculature immediately, intramuscular delivery produces a sustained release effect
Reduces complexity for multi compound use
Interaction Neuronal cells, myoblast, T cells, B cells, NK cells Ligand/Receptor IGF-I receptor, Insulin receptor isoform A, and IGF-II receptor (M-6-P-R) Bioactivity Human LR3 IGF-1 induces the proliferation of MCF-7 human epithelial cells
This is because an intramuscular injection allows you to bypass the digestive system so stomach absorption is not an issue